<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167722</url>
  </required_header>
  <id_info>
    <org_study_id>19HH5065</org_study_id>
    <nct_id>NCT04167722</nct_id>
  </id_info>
  <brief_title>How Does Prostate Cancer Metastasize? Studying the Role of Secreted Packages (Exosomes) From Fat Tissue in Lean and Obese Patients</brief_title>
  <acronym>EXOPRO</acronym>
  <official_title>The EXOPRO Study: How Does Prostate Cancer Metastasize? Understanding the Role of Exosomal Communication in Lean vs Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Experimental Cancer Medicine Centres</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will be collecting prostate and fat tissue from participants undergoing
      radical prostatectomy to culture and study in the laboratory.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both obesity and prostate cancer are major health problems in the UK, affecting 1 in 3 and 1
      in 8 men respectively. Moreover, obesity increases the risk of developing aggressive disease
      and the risk of prostate cancer spreading. How this happens is not known. The investigators
      want to understand how fat cells communicate with prostate cancer cells. Investigators will
      be collecting prostate and fat tissue from radical prostatectomy participants for culture, in
      particular to look at exosome communication.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine functional differences of peri-prostatic adipose tissue from lean vs obese patients on prostate cancer cell lines</measure>
    <time_frame>Through to study completion, on average 3 years</time_frame>
    <description>Proliferation, migration, invasion, apoptosis and epthelial-mesenchymal transition assays will be performed using isolated exosomes on prostate cancer cell lines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of exosomal small RNAs transferred between human adipose tissue to prostate cancer cells lines</measure>
    <time_frame>Through to study completion, on average 3 years</time_frame>
    <description>Exosomal RNA transferred from human adipose tissue to prostate cancer cell lines will be isolated using a tagged magnetic bead isolation method and sequenced to identify transferred small RNAs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess how exosomal small RNAs from lean vs obese patients affect cancer regulation</measure>
    <time_frame>Through to study completion, on average 3 years</time_frame>
    <description>Prostate cancer cell lines will be treated with isolated exosomes, then parental and treated cells sequenced to identify differentially expressed RNA and underlying changes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attempt to replicate functional changes observed</measure>
    <time_frame>Through to study completion, on average 3 years</time_frame>
    <description>Treatment of prostate cancer cell lines with microRNA mimics or inhibitors and comparison of changes with exosome treated cell lines</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese patients</arm_group_label>
    <description>BMI &gt; 25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean patients</arm_group_label>
    <description>BMI &lt; or = 25</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic Radical Prostatectomy</intervention_name>
    <description>Routine NHS Radical Prostatectomy</description>
    <arm_group_label>Lean patients</arm_group_label>
    <arm_group_label>Obese patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Prostate cancer tissue, benign prostate tissue, peri-prostatic adipose tissue, omental
      adipose tissue, blood, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Obese vs lean patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All men undergoing radical prostatectomy at Charing Cross Hospital

        Exclusion Criteria:

          -  Patients unable to consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Biological male only (can include transgender women)</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Bevan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mathias Winkler, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College Healthcare NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph Tam, MBBCh</last_name>
    <phone>+442075942135</phone>
    <email>j.tam18@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Becky Ward</last_name>
    <phone>+442075949459</phone>
    <email>becky.ward@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charing Cross Hospital, Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W68RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Winkler, FRCS</last_name>
      <phone>+44203311234</phone>
      <email>mathias.winkler@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Joseph Tam, MBBCh</last_name>
      <phone>+442075942135</phone>
      <email>j.tam18@imperial.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Mathias Winkler, FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Tam, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte Bevan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.imperial.ac.uk/department-surgery-cancer/research/cancer/research-areas/clinical-trials/exopro-study/</url>
    <description>EXOPRO Study Website</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Obesity</keyword>
  <keyword>Exosomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcomes will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available within 6 to 12 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external independent review panel. Regulators will be required to sign a data access agreement.</ipd_access_criteria>
    <ipd_url>https://www.imperial.ac.uk/department-surgery-cancer/research/cancer/research-areas/clinical-trials/exopro-study/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

